Dutch cryptocurrency service provider Amdax has announced that it raised over $23 million to establish a Bitcoin treasury company. The new entity, called AMBTS, will be listed on Amsterdam’s Euronext stock exchange. According to reports, investors from the initial funding round have already committed the full $23.3 million. Related Reading: Insider Trading Suspicions Mount As […]Dutch cryptocurrency service provider Amdax has announced that it raised over $23 million to establish a Bitcoin treasury company. The new entity, called AMBTS, will be listed on Amsterdam’s Euronext stock exchange. According to reports, investors from the initial funding round have already committed the full $23.3 million. Related Reading: Insider Trading Suspicions Mount As […]

Bitcoin Treasury Race Heats Up As Dutch Firm Shoots For $23-M Launch

Dutch cryptocurrency service provider Amdax has announced that it raised over $23 million to establish a Bitcoin treasury company.

The new entity, called AMBTS, will be listed on Amsterdam’s Euronext stock exchange. According to reports, investors from the initial funding round have already committed the full $23.3 million.

Targeting A Massive Share Of Bitcoin

AMBTS has a goal that stands out in its ambition: to eventually acquire 210,000 BTC, or about 1% of the total Bitcoin supply that will ever exist.

At today’s prices, that amount is worth more than $23 billion. The company says it wants to build value for its shareholders by expanding its Bitcoin holdings and increasing crypto per share, depending on market conditions.

The move reflects a growing wave of companies taking the treasury approach with Bitcoin. This strategy, popularized in 2020 by Michael Saylor’s Strategy, has steadily gained ground among public companies and private firms alike.

While some corporations simply add BTC to their balance sheets, others have been set up entirely to accumulate the digital asset.

Companies Building Bitcoin Treasuries

The list of firms building reserves goes beyond crypto-focused businesses. Strategy, formerly MicroStrategy, holds over 632,000 BTC, the largest corporate stash. Tesla also keeps Bitcoin in reserve, while Block, Inc. (formerly Square) added it to its treasury as well.

Japan’s Metaplanet is raising funds for more Bitcoin, and Dutch firm Amdax launched AMBTS to target 1% of supply. MercadoLibre and Norway’s Aker have also built reserves, showing the global spread of this trend.

Canadian video-sharing platform Rumble has also revealed holdings in digital currency, adding to the list of firms holding the asset as part of their long-term strategy.

On the other side, firms established with the sole intention of crypto acquisition are increasing their stacks. Each coin they add to their coffers takes more BTC out of circulation, which tightens supply.

Jockeying For Position

AMBTS, while still in its infancy, is putting itself squarely in the running for the treasury competition. Having raised $23.3 million and positioned itself to scale its holdings exponentially, the company has put itself among the increasingly large contingent of institutions viewing Bitcoin as a strategic reserve asset, not simply another investment.

Featured image from Unsplash, chart from TradingView

Market Opportunity
MemeCore Logo
MemeCore Price(M)
$1.6358
$1.6358$1.6358
+2.79%
USD
MemeCore (M) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26